Cargando…

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer

OBJECTIVE: The choice of chemotherapeutic regimen for triple-negative breast cancer (TNBC) remains controversial. Homologous recombination deficiency (HRD) has attracted increasing attention in informing chemotherapy treatment. This study was aimed at investigating the feasibility of HRD as a clinic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yimeng, Wang, Xue, Du, Feng, Yue, Jian, Si, Yiran, Zhao, Xiaochen, Cui, Lina, Zhang, Bei, Bei, Ting, Xu, Binghe, Yuan, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978893/ https://www.ncbi.nlm.nih.gov/pubmed/36861447 http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0525

Ejemplares similares

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers
por: ter Brugge, Petra, et al.
Publicado: (2023)

Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis
por: Chai, Yue, et al.
Publicado: (2022)

Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis
por: Zhang, Liulu, et al.
Publicado: (2022)

Platinum‐based chemotherapy for early triple‐negative breast cancer
por: Mason, Sofia RE, et al.
Publicado: (2023)

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer
por: Wen, Hao, et al.
Publicado: (2022)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration
por: Tsang, Erica S., et al.
Publicado: (2023)

Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
por: Botrus, Gehan, et al.
Publicado: (2022)

Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis
por: Lin, Canling, et al.
Publicado: (2022)

Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis
por: LIU, MIAO, et al.
Publicado: (2013)

Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis
por: Chen, Yimeng, et al.
Publicado: (2021)

Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies
por: Pokataev, Ilya, et al.
Publicado: (2020)

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
por: Feng, Zheng, et al.
Publicado: (2023)

Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes
por: Emelyanova, Marina, et al.
Publicado: (2022)

Platinum-Based Neoadjuvant Chemotherapy Before Radical Prostatectomy for Locally Advanced Prostate Cancer With Homologous Recombination Deficiency: A Case Report
por: Zhuang, Junlong, et al.
Publicado: (2022)

ZNF76 predicts prognosis and response to platinum chemotherapy in human ovarian cancer
por: Hua, Tian, et al.
Publicado: (2021)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair Deficiency
por: Liao, Gaoming, et al.
Publicado: (2022)

A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer
por: Feng, Wuna, et al.
Publicado: (2021)

Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair
por: Ratner, Elena S, et al.
Publicado: (2016)

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial
por: Bonnet, Elise, et al.
Publicado: (2022)

ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy
por: Baiomy, Mohamed Ali EL, et al.
Publicado: (2017)

Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis
por: Li, Zhen-Yu, et al.
Publicado: (2020)

Targeting glutamine metabolism enhances responses to platinum-based chemotherapy in triple-negative breast cancers (TNBC)
por: Hong, Jiaxin, et al.
Publicado: (2022)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer
por: Collier, Katharine A., et al.
Publicado: (2021)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes
por: da Costa, Alexandre A. B. A., et al.
Publicado: (2019)

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
por: Tian, Hao, et al.
Publicado: (2021)

Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer
por: Liao, Gaoming, et al.
Publicado: (2021)

Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status
por: Li, Yongmei, et al.
Publicado: (2022)

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients
por: de Boo, Leonora W., et al.
Publicado: (2022)

Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression
por: KHALAF, DANIEL, et al.
Publicado: (2014)

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
por: Caramelo, Olga, et al.
Publicado: (2019)

Platinum-Based Chemotherapy and Immunotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis and Indirect Treatment Comparison
por: He, Qin, et al.
Publicado: (2021)

Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer
por: Zhang, Linlin, et al.
Publicado: (2022)

Homologous recombination deficiency and glycolysis‐related pathway in adjuvant chemotherapy for triple‐negative breast cancer: A genomic landscape and biomarker assessment of the PATTERN trial
por: Zhu, Si‐Yuan, et al.
Publicado: (2021)

The efficacy and safety of platinum-based chemotherapy for ovarian cancer in pregnancy: A protocol for systematic review and meta-analysis
por: Wang, Bei, et al.
Publicado: (2022)

Genetic and functional homologous repair deficiency as biomarkers for platinum sensitivity in TNBC: A case report
por: Gomez-Puerto, Diego, et al.
Publicado: (2022)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tjab2fe0rmf4m7dunchp49srlb